Brief: Iovance's Amtagvi Granted Approval For Treatment Of Advanced Melanoma In Australia
03/06/2026 21:52
BRIEF-Iovance's Amtagvi Granted Approval For Treatment Of Advanced Melanoma In Australia June 3 (Reuters) - Iovance Biotherapeutics Inc IOVA.O:
IOVANCE’S AMTAGVI® (LIFILEUCEL) GRANTED APPROVAL FOR THE TREATMENT OF ADVANCED MELANOMA IN AUSTRALIA
Source text: ID:nGNX8FbXY2
Further company coverage: IOVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies